Antibiotic Stewardship Policies Tackle Growing Incidences of Antibiotic Resistance in cUTI Patients

Urinary tract infection (UTI) is one of the most prevalent health issues in most people. UTI is more common in women as compared to men, as women face health complications such as menopause, pregnancy, and certain side effects of birth control measures. However, on a global level, the urinary tract infection treatment market is challenged, as individuals are hesitant to consult doctors and healthcare providers for appropriate diagnosis.

Ongoing research and development activities in the urinary tract infection treatment market suggest the predictive factors of multidrug-resistant gram-negative bacteria in hospitalized patients suffering from complicated urinary tract infection (cUTI). Stakeholders are using the mixed-effects logistic regression model to study the symptoms in patients. Results show that, the antibiotic resistance for gram-negative bacteria is high in patients suffering from cUTI. Thus, appropriate diagnosis with healthcare providers and active enforcement of antibiotic stewardship policies will reduce the incidences of multi-drug antibiotic abstinence in patients for the treatment for complicated urinary tract infection.

urinary tract infection treatment market infographic

To know the scope of our report Get a Sample on Urinary Tract Infection Treatment Market

Market Players to Increase Awareness about Statutory Usage of Catheters

Patients with renal diseases are more susceptible to the risk of being exposed to urinary tract infection, due to long stays in the hospital, non-sanitized urinary catheters, and manipulations caused during urological treatment. As a result, healthcare providers in the urinary tract infection treatment market need to broaden the monitoring measures for patients, post-hospitalization, to reduce the incidences of urinary tract infection. Market players can create awareness in patients to carefully use urinary catheters and avoid unnecessary catheterization in patients.

On the other hand, healthcare providers are encountering increased incidences of community-acquired urinary tract infection caused by the escherichia coli (E. Coli) pathogen due to antibiotic resistance in patients. Thus, stakeholders in the urinary tract infection treatment market must cater to the growing need for effective antibiotic medication for UTI caused due to the E. Coli pathogen.

Get a glimpse of the in-depth analysis through our Report Brochure

Smartphone Apps and Instant Urine Cultures Serve as Cost-effective Remedies in UTI Treatment

Stakeholders in the UTI treatment market are developing new smartphone apps designed for women. These apps are created by on-boarding several doctors and pharmacies. With the growing influx of digitization in the healthcare industry, stakeholders can eliminate the issue of long-queue appointments with general practitioners for individuals. With effective diagnosis from doctors through the app, doctors can prescribe the right medication for the treatment of urinary tract infection, and pharmacists can supply home-testing kits and other medicinal antibiotics on demand. This digitization phenomena has created a win-win situation for stakeholders and healthcare providers, as well as pharmacists.

One of the biggest challenges that stakeholders operating in the urinary tract infection treatment market are facing is the antibiotic resistance for the treatment of urinary tract infection, even in healthy individuals with strong immune systems. As such, they are tackling the issue of antibiotic resistance with high-end antibiotics. Players operating in the urinary tract infection treatment market are also developing cost-effective solutions such as instant urine cultures to assess the resistance levels of individuals for antibiotics. For instance, in November 2018, Allergan — a leading pharmaceutical company, announced the launch of the FDA accepted supplemental drug ? AVYCAZ, for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections, for patients between the age group of 3 months to 18 years.

urinary tract infection treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint on the UTI Treatment Market

Analysts of the urinary tract infection treatment market portray a promising future for stakeholders during the forecast period of 2019-2027. Market players need to focus on innovating treatment options for urinary tract infection catering to complicated urinary tract infection, as currently cUTI accounts for ~82% of the market value share. Manufacturers in the UTI treatment market can build strategic tie-ups with hospital pharmacists, as they dominate the market value share, amounting to ~47%, though, retail pharmacists will have high growth potential in the coming years. Market players are challenged with high antibiotic resistance in UTI patients. This challenge can be overcome with increased offerings for at-home instant urine culture tests and the development of smartphone apps.

  • According to Transparency Market Research’s latest report on the global urinary tract infection treatment market for the historical period of 2017–2018 and forecast period of 2019-2027, rise in the awareness about urinary tract infection among women and increase in the adoption of new diagnostic tests are projected to boost the growth of the global urinary tract infection treatment market.
  • According to the report, the global urinary tract infection treatment market was valued at ~US$ 5.9 Bn in 2018 and is anticipated to expand at a CAGR of ~3% from 2019 to 2027.

Rise in Prevalence of Urinary Tract Infection (UTI): A Key Driver

  • Urinary tract infection (UTI) is one of the chronic diseases associated with the bladder, urethra, ureter, and kidneys. Over-reliance and high consumption of antibiotics are likely to increase antibiotic resistance in most UTI causing pathogens. This is projected to increase the prevalence of UTI in the near future.
  • According to the Pharmacotherapy Self-Assessment Program: Hematology/Oncology, in the U.S., around 60% women have symptomatic UTI during their lifetime, and around 10% women have one or more than one UTI episodes each year.
  • According to the National Institute for Health Research, an estimated 92 million people contracted urinary tract infection across the globe in 2013.
  • Most urinary tract infections are caused due to the presence of E. coli. According to a study published in the International Journal of Contemporary Medical Research, approximately 37.4% of UTIs were caused due to E. coli during 2016–2017.

Development of New Antibiotics and Advancements in Diagnosis of UTI

  • Key market players in the urinary tract infection treatment market focus on the development of new antibiotics for the treatment of urinary tract infections. In July 2019, the U.S. Food and Drug Administration approved the antibacterial drug – Recarbrio - for the treatment of complicated UTI and complicated intra-abdominal infection in adults.
  • In June 2018, Achaogen, Inc. received the U.S. Food and Drug Administration approval for ZEMDRI, for the treatment of complicated urinary tract infection in adults.
  • Biosensor is an advanced platform for the diagnosis of urinary tract infection. Biosensors can be integrated with microfluidic technology for point-of-care applications to improve UTI diagnosis.
  • New assays such as flow cytometry, MALDI-TOF mass spectrometry, fluorescence in situ hybridization, and multiplex PCR also help improve the diagnosis of urinary tract infections.

Introduction of Generic Drugs Restrains Market

  • The launch of new generic products in the market is a major factor hampering the growth of the global urinary tract infection treatment market.
  • In June 2018, Aurobindo Pharma received the U.S. Food and Drug Administration approval for the manufacturing and marketing of the generic Entrapenem injection. It is a generic version of Invanz offered by Merck Sharp & Dohme Corp.
  • In July 2018, Lupin received approval from the U.S. Food and Drug Administration for generic Nitrofurantoin Capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used in the treatment of UTI that occurs due to Staphylococcus aureus, enterococci, and others.

Global Urinary Tract Infection Treatment Market: Competitive Landscape

  • This report profiles major players in the global urinary tract infection treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.
  • The urinary tract infection treatment market is moderately fragmented, with the presence of a few large-scale players present in international markets and numerous small-scale players in regional markets. The top 4 to 5 players hold a majority share of the global urinary tract infection treatment market.

Prominent players operating in the urinary tract infection treatment market include

  • Allergan
  • Bayer AG
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Lupin Ltd.
  • Merck & Co., Inc
  • (Merck Sharp & Dohme Corp)
  • Dr. Reddy’s Laboratories Ltd.
  • ‚ÄčAlmirall, S.A

Global Urinary Tract Infection Treatment Market: Key Developments

Key players in the global urinary tract infection treatment market engage in new product development and approvals, key mergers & acquisitions, and collaborations. These strategies by industry players are likely to augment the global urinary tract infection treatment market. Some developments in the global urinary tract infection treatment market are as follows:

  • In March 2019, Allergan received the U.S. Food and Drug Administration approval for the supplemental New Drug Application for AVYCAZ to expand the label to include pediatric patients three months and older, for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infections (cIAI). This is the first FDA approval for cUTI and cIAI for pediatric patients.
  • In August 2016, Pfizer, Inc. entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its anti-infectives business. This acquisition enabled the company to expand and broaden its access to the anti-infective product portfolio. Moreover, the acquisition strengthened Pfizer, Inc.’s essential health business segment.
  • In October 2016, Fimbrion Therapeutics, Inc. and GlaxoSmithKline plc entered into a collaboration to develop a small molecule drug for the treatment and prevention of urinary tract infection.

In the global urinary tract infection treatment market report, we have discussed individual strategies, followed by company profiles of the manufacturers of urinary tract infection products. The ‘Competitive Landscape’ section is included in the market report to provide readers with a dashboard view and a company market share analysis of the key players operating in the global urinary tract infection treatment market.

Urinary Tract Infection Treatment Market - Segmentation

The comprehensive study on the urinary tract infection treatment market provides a comprehensive analysis of the market attractiveness by offering insights into the key segments. The urinary tract infection treatment market has been segregated on the basis of disease, drug class, pathogen, source of infection, gender, distribution channel, and region. The global study highlights a country-wise analysis to lend incisive insights about the healthcare innovations of urinary tract infection treatments.

Each of the segments included in this report help in gaining crucial insights into the urinary tract infection treatment market. The study on the urinary tract infection treatment market offers historical, current, and futuristic trends influencing its growth. In addition to this, it covers value chain analysis, Y-o-Y growth analysis, and supply chain analysis.

Disease

Uncomplicated UTI

Complicated UTI

Drug Class

Quinolones

Beta-lactams

Macrolides

Aminoglycosides

Others

Pathogen

E. Coli

Pseudomonas aeruginosa

Enterococcus spp

K. pneumoniae

S. aureus

Others

Source of Infection

Hospital-acquired UTI

Community-acquired UTI

Gender

Female

Male

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

 

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Urinary Tract Infection Treatment Market

4. Market Overview

    4.1. Introduction

          4.1.1. Disease Definition

          4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

          4.3.1. Drivers

                      4.3.1.1 Rise in prevalence of UTI

                      4.3.1.2. Increase in number of hospital acquired infection

                      4.3.1.3. Rise in awareness about women's health

                      4.3.1.4. Introduction of new diagnostic test

                      4.3.1.5. Development of new antibiotics

          4.3.2. Restraints

                      4.3.2.1 Introduction of generic drug

                      4.3.2.2. Patent Expiry

          4.3.3. Opportunities

    4.4. Global Urinary Tract Infection Treatment Market Analysis and Forecast, 2017–2027

5. Market Outlook

    5.1. Epidemiology Overview of UTI by Key Countries (Prevalence, Incidence, Overall Burden)

    5.2. Pipeline Analysis

    5.3. Overview of Guidelines for Diagnosis & Treatment of UTI’s 

    5.4. Reimbursement Scenario

    5.5. Overview of Multi-Drug Resistance Pathogen and Infections (Infection Types & Prevalence, Most drug resistant Bacterial Strains)

    5.6. Advancements in UTI diagnosis (Rapid Action Tests, New Assays in Anti-microbial susceptibility testing, etc.)

6. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Disease 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Disease, 2017–2027

          6.3.1. Uncomplicated UTI 

          6.3.2. Complicated UTI

    6.4. Market Attractiveness, by Disease 

7. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Drug Class 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Drug Class, 2017–2027

          7.3.1. Quinolones

          7.3.2. Beta-lactams

          7.3.3. Macrolides

          7.3.4. Aminoglycosides

          7.3.5. Others

    7.4. Market Attractiveness, by Drug Class 

8. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Pathogen 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Pathogen, 2017–2027

          8.3.1. E. coli

          8.3.2. Pseudomonas aeruginosa

          8.3.3. Enterococcus spp

          8.3.4. K. pneumoniae

          8.3.5. S. aureus

          8.3.6. Others

    8.4. Market Attractiveness, by Pathogen 

9. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Source of Infection

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Source of Infection, 2017–2027

          9.3.1. Hospital Acquired UTI

          9.3.2. Community Acquired UTI 

    9.4. Market Attractiveness, by Source of Infection

10. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Gender 

    10.1. Introduction & Definition

    10.2. Key Findings / Developments

    10.3. Market Value Forecast, by Gender, 2017–2027

          10.3.1. Female

          10.3.2. Male

    10.4. Market Attractiveness, by Gender 

11. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Distribution Channel 

    11.1. Introduction & Definition

    11.2. Key Findings / Developments

    11.3. Market Value Forecast, by Distribution Channel, 2017–2027

          11.3.1. Retail Pharmacies

          11.3.2. Hospital Pharmacies

          11.3.3. Online Pharmacies 

    11.4. Market Attractiveness, by Distribution Channel 

12. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Region

    12.1. Key Findings

    12.2. Market Value Forecast, by Region

          12.2.1. North America 

          12.2.2. Europe 

          12.2.3. Asia Pacific 

          12.2.4. Latin America 

          12.2.5. Middle East & Africa 

    12.3. Market Attractiveness, by Country/Region

13. North America Urinary Tract Infection Treatment Market Analysis and Forecast

    13.1. Introduction

          13.1.1. Key Findings

    13.2. Market Value Forecast, by Disease, 2017–2027

          13.2.1. Uncomplicated UTI 

          13.2.2. Complicated UTI

    13.3. Market Value Forecast, by Drug Class, 2017–2027

          13.3.1. Quinolones

          13.3.2. Beta-lactams

          13.3.3. Macrolides

          13.3.4. Aminoglycosides

          13.3.5. Others

    13.4. Market Value Forecast, by Pathogen, 2017–2027

          13.4.1. E. coli

          13.4.2. Pseudomonas aeruginosa

          13.4.3. Enterococcus spp

          13.4.4. K. pneumoniae

          13.4.5. S. aureus

          13.4.6. Others

    13.5. Market Value Forecast, by Source of Infection, 2017–2027

          13.5.1. Hospital Acquired UTI

          13.5.2. Community Acquired UTI 

    13.6. Market Value Forecast, by Gender, 2017–2027

          13.6.1. Female

          13.6.2. Male

    13.7. Market Value Forecast, by Distribution Channel, 2017–2027

          13.7.1. Retail Pharmacies

          13.7.2. Hospital Pharmacies

          13.7.3. Online Pharmacies 

    13.8. Market Value Forecast, by Country, 2017–2027

          13.8.1. U.S.

          13.8.2. Canada

    13.9. Market Attractiveness Analysis 

          13.9.1. By Disease 

          13.9.2. By Drug Class 

          13.9.3. By Pathogen 

          13.9.4. By Source of Infection

          13.9.5. By Gender 

          13.9.6. By Distribution Channel 

          13.9.7. By Country

14. Europe Urinary Tract Infection Treatment Market Analysis and Forecast

    14.1. Introduction

          14.1.1. Key Findings

    14.2. Market Value Forecast, by Disease, 2017–2027

          14.2.1. Uncomplicated UTI 

          14.2.2. Complicated UTI

    14.3. Market Value Forecast, by Drug Class, 2017–2027

          14.3.1. Quinolones

          14.3.2. Beta-lactams

          14.3.3. Macrolides

          14.3.4. Aminoglycosides

          14.3.5. Others

    14.4. Market Value Forecast, by Pathogen, 2017–2027

          14.4.1. E. coli

          14.4.2. Pseudomonas aeruginosa

          14.4.3. Enterococcus spp

          14.4.4. K. pneumoniae

          14.4.5. S. aureus

          14.4.6. Others

    14.5. Market Value Forecast, by Source of Infection, 2017–2027

          14.5.1. Hospital Acquired UTI

          14.5.2. Community Acquired UTI 

    14.6. Market Value Forecast, by Gender, 2017–2027

          14.6.1. Female

          14.6.2. Male

    14.7. Market Value Forecast, by Distribution Channel, 2017–2027

          14.7.1. Retail Pharmacies

          14.7.2. Hospital Pharmacies

          14.7.3. Online Pharmacies 

    14.8. Market Value Forecast, by Country/Sub-region, 2017–2027

          14.8.1. Germany

          14.8.2. U.K.

          14.8.3. France

          14.8.4. Spain

          14.8.5. Italy

          14.8.6. Rest of Europe

    14.9. Market Attractiveness Analysis 

          14.9.1. By Disease 

          14.9.2. By Drug Class 

          14.9.3. By Pathogen 

          14.9.4. By Source of Infection

          14.9.5. By Gender 

          14.9.6. By Distribution Channel 

          14.9.7. By Country/Sub-region

15. Asia Pacific Urinary Tract Infection Treatment Market Analysis and Forecast

    15.1. Introduction

          15.1.1. Key Findings

    15.2. Market Value Forecast, by Disease, 2017–2027

          15.2.1. Uncomplicated UTI 

          15.2.2. Complicated UTI

    15.3. Market Value Forecast, by Drug Class, 2017–2027

          15.3.1. Quinolones

          15.3.2. Beta-lactams

          15.3.3. Macrolides

          15.3.4. Aminoglycosides

          15.3.5. Others

    15.4. Market Value Forecast, by Pathogen, 2017–2027

          15.4.1. E. coli

          15.4.2. Pseudomonas aeruginosa

          15.4.3. Enterococcus spp

          15.4.4. K. pneumoniae

          15.4.5. S. aureus

          15.4.6. Others

    15.5. Market Value Forecast, by Source of Infection, 2017–2027

          15.5.1. Hospital Acquired UTI

          15.5.2. Community Acquired UTI 

    15.6. Market Value Forecast, by Gender, 2017–2027

          15.6.1. Female

          15.6.2. Male

    15.7. Market Value Forecast, by Distribution Channel, 2017–2027

          15.7.1. Retail Pharmacies

          15.7.2. Hospital Pharmacies

          15.7.3. Online Pharmacies 

    15.8. Market Value Forecast, by Country/Sub-region, 2017–2027

          15.8.1. China

          15.8.2. Japan

          15.8.3. India

          15.8.4. Australia & New Zealand

          15.8.5. Rest of Asia Pacific

    15.9. Market Attractiveness Analysis 

          15.9.1. By Disease 

          15.9.2. By Drug Class 

          15.9.3. By Pathogen 

          15.9.4. By Source of Infection

          15.9.5. By Gender 

          15.9.6. By Distribution Channel 

          15.9.7. By Country/Sub-region

16. Latin America Urinary Tract Infection Treatment Market Analysis and Forecast

    16.1. Introduction

          16.1.1. Key Findings

    16.2. Market Value Forecast, by Disease, 2017–2027

          16.2.1. Uncomplicated UTI 

          16.2.2. Complicated UTI

    16.3. Market Value Forecast, by Drug Class, 2017–2027

          16.3.1. Quinolones

          16.3.2. Beta-lactams

          16.3.3. Macrolides

          16.3.4. Aminoglycosides

          16.3.5. Others

    16.4. Market Value Forecast, by Pathogen, 2017–2027

          16.4.1. E. coli

          16.4.2. Pseudomonas aeruginosa

          16.4.3. Enterococcus spp

          16.4.4. K. pneumoniae

          16.4.5. S. aureus

          16.4.6. Others

    16.5. Market Value Forecast, by Source of Infection, 2017–2027

          16.5.1. Hospital Acquired UTI

          16.5.2. Community Acquired UTI 

    16.6. Market Value Forecast, by Gender, 2017–2027

          16.6.1. Female

          16.6.2. Male

    16.7. Market Value Forecast, by Distribution Channel, 2017–2027

          16.7.1. Retail Pharmacies

          16.7.2. Hospital Pharmacies

          16.7.3. Online Pharmacies 

    16.8. Market Value Forecast, by Country/Sub-region, 2017–2027

          16.8.1. Brazil          

          16.8.2. Mexico

          16.8.3. Rest of Latin America

    16.9. Market Attractiveness Analysis 

          16.9.1. By Disease

          16.9.2. By Drug Class 

          16.9.3. By Pathogen 

          16.9.4. By Source of Infection

          16.9.5. By Gender 

          16.9.6. By Distribution Channel 

          16.9.7. By Country/Sub-region

17. Middle East & Africa Urinary Tract Infection Treatment Market Analysis and Forecast

    17.1. Introduction

          17.1.1. Key Findings

    17.2. Market Value Forecast, by Disease, 2017–2027

          17.2.1. Uncomplicated UTI 

          17.2.2. Complicated UTI

    17.3. Market Value Forecast, by Drug Class, 2017–2027

          17.3.1. Quinolones

          17.3.2. Beta-lactams

          17.3.3. Macrolides

          17.3.4. Aminoglycosides

          17.3.5. Others

    17.4. Market Value Forecast, by Pathogen, 2017–2027

          17.4.1. E. coli

          17.4.2. Pseudomonas aeruginosa

          17.4.3. Enterococcus spp

          17.4.4. K. pneumoniae

          17.4.5. S. aureus

          17.4.6. Others

    17.5. Market Value Forecast, by Source of Infection, 2017–2027

          17.5.1. Hospital Acquired UTI

          17.5.2. Community Acquired UTI 

    17.6. Market Value Forecast, by Gender, 2017–2027

          17.6.1. Female

          17.6.2. Male

    17.7. Market Value Forecast, by Distribution Channel, 2017–2027

          17.7.1. Retail Pharmacies

          17.7.2. Hospital Pharmacies

          17.7.3. Online Pharmacies 

    17.8. Market Value Forecast, by Country/Sub-region, 2017–2027

          17.8.1. GCC Countries

          17.8.2. South Africa

          17.8.3. Rest of Middle East & Africa

    17.9. Market Attractiveness Analysis 

          17.9.1. By Disease 

          17.9.2. By Drug Class 

          17.9.3. By Pathogen 

          17.9.4. By Source of Infection

          17.9.5. By Gender 

          17.9.6. By Distribution Channel 

          17.9.7. By Country/Sub-region

18. Competition Landscape

    18.1. Market Player - Competition Matrix (By Tier and Size of companies)

    18.2. Market Share Analysis/Ranking, by Company, 2018

    18.3. Company Profiles

          18.3.1. Allergan

                   18.3.1.1. Company Overview

                   18.3.1.2. Product Portfolio

                   18.3.1.3. SWOT Analysis

                   18.3.1.4. Financial Overview

                   18.3.1.5. Strategic Overview

          18.3.2. Bayer AG 

                   18.3.2.1. Company Overview

                   18.3.2.2. Product Portfolio

                   18.3.2.3. SWOT Analysis

                   18.3.2.4. Financial Overview

                   18.3.2.5. Strategic Overview

          18.3.3. Pfizer, Inc.

                   18.3.3.1. Company Overview

                   18.3.3.2. Product Portfolio

                   18.3.3.3. SWOT Analysis

                   18.3.3.4. Financial Overview

                   18.3.3.5. Strategic Overview

          18.3.4. GlaxoSmithKline plc

                   18.3.4.1. Company Overview

                   18.3.4.2. Product Portfolio

                   18.3.4.3. SWOT Analysis

                   18.3.4.4. Financial Overview

                   18.3.4.5. Strategic Overview

          18.3.5. Bristol-Myers Squibb Company

                   18.3.5.1. Company Overview

                   18.3.5.2. Product Portfolio

                   18.3.5.3. SWOT Analysis

                   18.3.5.4. Financial Overview

          18.3.6. Johnson & Johnson (Janssen Global Services, LLC)

                   18.3.6.1. Company Overview

                   18.3.6.2. Product Portfolio

                   18.3.6.3. SWOT Analysis

                   18.3.6.4. Financial Overview

                   18.3.6.5. Strategic Overview

          18.3.7. LUPIN

                   18.3.7.1. Company Overview

                   18.3.7.2. Product Portfolio                   

                   18.3.7.3. SWOT Analysis

                   18.3.7.4. Financial Overview

                   18.3.7.5. Strategic Overview

          18.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

                   18.3.8.1. Company Overview

                   18.3.8.2. Product Portfolio

                   18.3.8.3. SWOT Analysis

                   18.3.8.4. Financial Overview

                   18.3.8.5. Strategic Overview

          18.3.9. Dr. Reddy’s Laboratories Ltd 

                   18.3.9.1. Company Overview

                   18.3.9.2. Product Portfolio

                   18.3.9.3. SWOT Analysis

                   18.3.9.4. Financial Overview

          18.3.10. Almirall, S.A

                   18.3.10.1. Company Overview

                   18.3.10.2. Product Portfolio

                   18.3.10.3. SWOT Analysis

                   18.3.10.4. Financial Overview

                   18.3.10.5. Strategic Overview

List of Tables

Table 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 03: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 04: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 05: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 06: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 07: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 09: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 10: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 11: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 12: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 13: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 16: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 17: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 18: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 19: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 20: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 21: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 23: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 24: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 25: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 26: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 27: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 28: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 30: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 31: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 32: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 33: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 34: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 35: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 36: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 37: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 38: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 39: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 40: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 41: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 42: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figures

Figure 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn), by Pathogen, 2018
Figure 03: Market Snapshot - Top 2 Trends
Figure 04: Market Overview
Figure 05: Global Urinary Tract Infection Treatment Market Value Share, by Disease, 2018
Figure 06: Global Urinary Tract Infection Treatment Market Value Share, by Drug Class, 2018
Figure 07: Global Urinary Tract Infection Treatment Market Value Share, by Pathogen, 2018
Figure 08: Global Urinary Tract Infection Treatment Market Value Share, by Source of Infection, 2018
Figure 09: Global Urinary Tract Infection Treatment Market Value Share, by Gender, 2018
Figure 10: Global Urinary Tract Infection Treatment Market Value Share, by Distribution Channel, 2018
Figure 11: Global Urinary Tract Infection Treatment Value Share, by region, 2018
Figure 12: Global Urinary Tract Infection Treatment Market Value Share, by Region, 2018
Figure 13: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 14: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 15: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Uncomplicated UTI, 2017–2027
Figure 16: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Complicated UTI, 2017–2027
Figure 17: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2018–2027
Figure 18: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 19: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Quinolones, 2017–2027
Figure 20: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Beta-lactams, 2017–2027
Figure 21: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Macrolides, 2017–2027
Figure 22: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Aminoglycosides, 2017–2027
Figure 22: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
Figure 23: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 24: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 25: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by E. Coli, 2017–2027
Figure 26: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Pseudomonas aeruginosa, 2017–2027
Figure 27: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Enterococcus spp, 2017–2027
Figure 28: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by K. pneumoniae, 2017–2027
Figure 29: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by S. aureus, 2017–2027
Figure 30: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
Figure 31: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2018–2026
Figure 32: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 33: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Acquired UTI, 2017–2027
Figure 34: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Community Acquired UTI, 2017–2027
Figure 35: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2018–2026
Figure 36: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 37: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Female, 2017–2027
Figure 38: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Male, 2017–2027
Figure 39: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2018–2026
Figure 40: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 41: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027
Figure 42: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017–2027
Figure 43: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027
Figure 44: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2027
Figure 45: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 46: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Region, 2018–2026
Figure 47: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 48: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 49: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 50: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 51: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 52: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 53: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 54: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 55: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 56: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 57: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 58: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 59: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
Figure 60: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 61: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 62: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 63: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 64: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 65: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 66: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 67: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 68: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 69: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 70: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 71: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 72: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 73: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 74: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 75: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 76: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 77: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 78: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 79: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 80: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 81: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 82: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 83: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 84: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 85: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 86: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 87: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 88: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 89: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
Figure 90: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 91: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 92: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 93: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 94: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 95: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 96: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 97: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 98: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 99: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 100: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 101: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 102: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 103: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 104: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 105: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 106: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 107: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 108: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 109: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 110: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 111: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 112: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 113: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 115: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 116: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 117: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 118: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 119: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 120: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 121: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 122: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 123: Global Urinary Tract Infection Treatment Market Analysis, by Top Company Ranking, 2018
Figure 124: Global Urinary Tract Infection Treatment Market Share, by Company, 2017 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Urinary Tract Infection Treatment Market